Equities

OXB

OXB:LSE

OXB

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)809.00
  • Today's Change-3.00 / -0.37%
  • Shares traded158.96k
  • 1 Year change99.75%
  • Beta3.0186
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.

  • Revenue in GBP (TTM)151.21m
  • Net income in GBP-37.07m
  • Incorporated1996
  • Employees900.00
  • Location
    OXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 18 6578 3000Fax+44 18 6578 3001
  • Websitehttps://www.oxb.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		OXB:LSE since
announced		Transaction
value
RTP Operating LLC-Gene Therapy Viral Vector Manufacturing FacilityDeal completed07 Oct 202507 Oct 2025Deal completed27.00%4.50m
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Philogen SpA68.33m39.85m538.13m193.00538.13m193.00
Valneva SE156.17m-88.68m602.13m700.00602.13m700.00
Basilea Pharmaceutica AG Allschwil223.67m68.80m715.16m180.00715.16m180.00
Nanobiotix SA-12.19m-44.83m753.72m103.00753.72m103.00
Gubra A/S306.41m202.92m780.75m275.00780.75m275.00
Idorsia Ltd220.17m-111.68m857.35m938.00857.35m938.00
Inventiva SA11.81m-270.01m899.42m84.00899.42m84.00
Kuros Biosciences AG83.46m-4.45m932.78m122.00932.78m122.00
Evotec SE656.51m-138.00m949.27m4.79k949.27m4.79k
Oxford BioMedica plc151.21m-37.07m977.70m900.00977.70m900.00
Data as of Feb 06 2026. Currency figures normalised to OXB's reporting currency: UK Pound GBX

Institutional shareholders

41.75%Per cent of shares held by top holders
HolderShares% Held
Briarwood Chase Management LLCas of 20 Aug 202518.64m15.46%
Vulpes Investment Management Pte Ltd.as of 21 Mar 20258.45m7.01%
M&G Investment Management Ltd.as of 14 Jan 20265.69m4.72%
Hargreaves Lansdown Asset Management Ltd.as of 21 Mar 20253.48m2.88%
Threadneedle Asset Management Ltd.as of 29 Jan 20262.99m2.48%
Charles Schwab Investment Management, Inc.as of 01 Dec 20252.78m2.31%
BlackRock Investment Management (UK) Ltd.as of 29 Jan 20262.35m1.95%
Liontrust Investment Partners LLPas of 27 Jan 20262.28m1.89%
Banque Pictet & Cie SAas of 01 Dec 20252.07m1.72%
abrdn, Inc.as of 27 Jan 20261.59m1.32%
More ▼
Data from 30 Sep 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.